aripiprazole versus risperidone for treating schizophrenia

Efficacy of aripiprazole versus risperidone on body mass index for treating schizophrenia, a randomized double blind controlled clinical trial

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT201305233930N26

Enrollment

Registered

2014-11-01

Start date

2013-05-27

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia. Schizophrenia

Interventions

Intervention 1: Risperidone (up to 10 mg/day). Intervention 2: Aripiprazole (up to 30 mg/day).

Treatment - Drugs

Risperidone (up to 10 mg/day)

Aripiprazole (up to 30 mg/day)

Eligibility

Sex/Gender

All

Age

16 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: patients with schizophrenia aged between 16 to 65 years old. Exclusion criteria: serious uncontrolled medical condition such as hypothyroidism; pregnancy.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: baseline and at the end of this trial. Method of measurement: kilogram.;Height. Timepoint: Baseline and at the end of this trial. Method of measurement: Meter.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactAhmad Ghanizadeh

Shiraz University of Medical sciences

ghanizad@sina.tums.ac.ir+98 71 1627 3070

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026